trial

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCTId NCT03745820
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 195 (actual)
Sponsored by Biogen
Primary completion 2022-03-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
195 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-11-15
Primary completion
2022-03-23
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
BIIB104

Sponsors

BiogenLead Sponsor

Sites

60 total
Bentonville, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesLong Beach, United StatesMontclair, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesSan Diego, United StatesSan Diego, United StatesSan Rafael, United States

Linked catalysts

1
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cogn — primary completion2022-03-23

Facts & assertions

4 sourced
Enrollment
195
Phase
PHASE2
Primary Completion Date
2022-03-23
Status
COMPLETED
relationships
The graph out of here
drug
BIIB104
drug
lead_sponsor
Biogen
company
indication
Cognitive Impairment Associated With Schizophrenia
indication